Kalohexis doses first patients in 710GO Phase I trial for obesity

Kalohexis has dosed the first patients in its Phase I FIH clinical trial of 710GO, an oral dual MC3R/MC4R agonist to treat general obesity. The trial is expected to recruit around 100 healthy overweight or obese volunteers. 710GO is designed to activate the melanocortin system for more sustainable weight loss. Credit: New Africa / Shutterstock.com. Kalohexis has dosed the first patients in its Phase I first-in-human clinical trial of 710GO, an oral dual melanocortin-3 receptor/melanocortin-4 receptor (MC3R/MC4R) agonist for general obesity treatment. The randomised, double-blind, placebo-controlled trial includes single-ascending dose, 28-day multiple-ascending dose, and food effect components. Combine business intelligence…

Source: Clinical Trials Arena